CONSULTING AGREEMENTConsulting Agreement • March 13th, 2024 • Spero Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Consulting Agreement (the “Agreement”) is dated February 9, 2024 and is effective as of March 6, 2024 (the “Effective Date”) by and between Spero Therapeutics, Inc., with offices located at 675 Massachusetts Avenue, 14th Floor, Cambridge, MA 02139, together with its subsidiaries and affiliates (collectively, “Spero”) and Tamara Joseph (“Consultant”). Spero and Consultant shall be referred to individually as a “Party” and together as the “Parties”.
February 9, 2024 Ms. Tamara Joseph Arlington, MA 02476 Dear Tamara:Severance Agreement • March 13th, 2024 • Spero Therapeutics, Inc. • Pharmaceutical preparations
As was discussed with you, your employment with Spero Therapeutics, Inc. (the "Company") is ending. This letter is to summarize the terms of the separation package that the Company is willing to offer you as a result of your separation from employment. Please read this letter agreement (the “Letter Agreement”), which includes a general release, carefully. If you are willing to agree to its terms, please sign in the space provided below and return it to me so that your separation benefits can begin.
AMENDMENT 1 TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • March 13th, 2024 • Spero Therapeutics, Inc. • Pharmaceutical preparations
This Amendment 1 (“Amendment 1”) entered into as of July 4 2023 (“Amendment 1 Effective Date”), by and between Spero Therapeutics, Inc. (“Spero”) and GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”), hereby amends the Exclusive License Agreement between the Parties dated September 21, 2022 (the “Agreement”). Capitalized terms not otherwise defined in this Amendment 1 will have the same meanings as ascribed to such terms in the Agreement.
AMENDMENT 2 TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • March 13th, 2024 • Spero Therapeutics, Inc. • Pharmaceutical preparations
This Amendment 2 (“Amendment 2”) entered into as of December 20, 2023 (“Amendment 2 Effective Date”), by and between Spero Therapeutics, Inc. (“Spero”) and GlaxoSmithKline Intellectual Property (No. 3 Limited (“GSK”), hereby amends the Exclusive License Agreement between the Parties dated September 21, 2022, as amended on July 4, 2023, by Amendment 1 to Exclusive License Agreement (the “Agreement”). Capitalized terms not otherwise defined in this Amendment 2 will have the same meanings as ascribed to such terms in the Agreement.
